Tscan Therapeutics Inc (TCRX) Stock Price, Quote & News

Company Profile

TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT) is in Phase I clinical trial, as...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 399 9500

Website: www.tscan.com

Address:

830 Winter Street, Waltham, United States

notreload_ai Nov. 14 at 4:43 PM

$BTM $FISV $MNPR $PGR $TCRX -- MarketBeat

0 · Reply

aletz Nov. 13 at 3:38 PM

$TCRX https://www.biostockinfo.com/biotech-catalyst-ai-scanner-november-wk3/ TCRX selected by AI scanner again, fingers crossed for the rebound!

1 · Reply

JarvisFlow Nov. 13 at 12:54 PM

HC Wainwright & Co. has adjusted their stance on TScan Therapeutics ( $TCRX ), setting the rating to Buy with a target price of 10 → 7.

1 · Reply

Deliver1 Nov. 12 at 10:38 PM

$TCRX November 2025 Corporate Presentation - MUST READ! https://ir.tscan.com/static-files/1d066354-1ed3-4f4f-b97b-28806d9da9f5

0 · Reply

Elaine_Shrimp Nov. 12 at 8:24 PM

$TCRX found this through twitter 🤫🤫👀

0 · Reply

RMND Nov. 12 at 5:26 PM

$TCRX

0 · Reply

d_risk Nov. 12 at 4:26 PM

$TCRX - TScan Therapeutics Inc. Common Stock - 10Q - Updated Risk Factors TCRX’s latest 10-Q risk factors spotlight expanded losses, heavy reliance on proprietary platforms, new geopolitical and trade risks, detailed clinical and manufacturing hurdles, workforce cuts, and heightened IP, litigation, and inflation threats—while streamlining or removing prior disclosures on capital raising, patent law, and operational disruptions. #Biotechnology #InflationImpact #GeopoliticalRisks #IntellectualProperty #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/TCRX/10-Q/2025-11-12

0 · Reply

Deliver1 Nov. 12 at 1:57 PM

$TCRX TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update https://finance.yahoo.com/news/tscan-therapeutics-reports-third-quarter-120000677.html

0 · Reply

PiratesKingLuffy Nov. 12 at 3:09 AM

AMZE Expecting a big move here tomorrow. Very bullish close today!! AMZE has extended its partnership with Adobe Express, expanding platform access to creators in India — a market with over 2 million monetized creators and $350B in consumer spending. The integration lets users design and sell custom merchandise directly on Amaze, streamlining the path from creation to commerce. The expansion follows Amaze’s showcase at Adobe MAX 2025. Lets bank on AMZE such a gem here! $STOK $IOVA $TCRX $MOVE.X ..//

0 · Reply

SPYmyQQQ Nov. 11 at 8:43 PM

🎯 Target Hit 🏁 📨 From Nov 10, 2025 💊 $TCRX 💵 Entry: $1.0600 ✅ Exit: $1.2300 💰 P/L: +16.04% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 5, 2025, 7:00 AM EST - 9 days ago

TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

Nov 3, 2025, 6:30 AM EST - 11 days ago

TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027

Sep 17, 2025, 7:00 AM EDT - 2 months ago

TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025

Sep 3, 2025, 7:00 AM EDT - 2 months ago

TScan Therapeutics to Participate in Upcoming Investor Conferences

Aug 12, 2025, 7:00 AM EDT - 3 months ago

TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

May 28, 2025, 7:00 AM EDT - 6 months ago

TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

May 6, 2025, 7:00 AM EDT - 6 months ago

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Apr 28, 2025, 4:53 PM EDT - 7 months ago

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting

Mar 31, 2025, 7:00 AM EDT - 8 months ago

TScan Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 27, 2025, 7:00 AM EDT - 8 months ago

TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

Mar 7, 2025, 11:31 AM EST - 9 months ago

TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025

Mar 5, 2025, 7:00 AM EST - 9 months ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 7:00 AM EST - 9 months ago

TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 7:00 AM EST - 9 months ago

TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

Feb 10, 2025, 3:14 AM EST - 9 months ago

TScan Therapeutics: Finding Their Footing After An Eventful ASH Meeting

Dec 26, 2024, 7:00 AM EST - 11 months ago

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

Dec 23, 2024, 7:00 AM EST - 11 months ago

TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank

Dec 9, 2024, 5:45 PM EST - 1 year ago

TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition

Dec 5, 2024, 8:00 AM EST - 1 year ago

TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years

Dec 2, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy

Nov 5, 2024, 9:15 AM EST - 1 year ago

TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition

Oct 4, 2024, 9:05 AM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting

Aug 26, 2024, 10:09 AM EDT - 1 year ago

TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology

Aug 12, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jun 14, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Announces Updates to its Board of Directors

May 29, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies

May 13, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors

Apr 24, 2024, 4:05 PM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting

Apr 24, 2024, 11:03 AM EDT - 1 year ago

TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares

Apr 22, 2024, 5:01 PM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting

Apr 19, 2024, 10:05 AM EDT - 1 year ago

TScan Therapeutics Announces Closing of Upsized Public Offering

Apr 17, 2024, 12:30 AM EDT - 1 year ago

TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering

Apr 16, 2024, 4:25 PM EDT - 1 year ago

TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

Apr 16, 2024, 4:01 PM EDT - 1 year ago

TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities

Apr 8, 2024, 8:00 AM EDT - 1 year ago

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D.

Apr 2, 2024, 7:00 AM EDT - 1 year ago

TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference

Mar 6, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 28, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Feb 26, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

Feb 14, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR

Feb 6, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development

Jan 29, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer

Jan 18, 2024, 7:00 AM EST - 1 year ago

TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR

Jan 4, 2024, 7:00 AM EST - 2 years ago

TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress

Dec 27, 2023, 7:00 PM EST - 2 years ago

TScan: Two 2024 TCR-T Data Readouts Could Bring Significant Value

Dec 9, 2023, 12:00 PM EST - 2 years ago

TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition

Dec 7, 2023, 7:00 AM EST - 2 years ago

TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations

Dec 4, 2023, 4:05 PM EST - 2 years ago

TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and Exposition

notreload_ai Nov. 14 at 4:43 PM

$BTM $FISV $MNPR $PGR $TCRX -- MarketBeat

0 · Reply

aletz Nov. 13 at 3:38 PM

$TCRX https://www.biostockinfo.com/biotech-catalyst-ai-scanner-november-wk3/ TCRX selected by AI scanner again, fingers crossed for the rebound!

1 · Reply

JarvisFlow Nov. 13 at 12:54 PM

HC Wainwright & Co. has adjusted their stance on TScan Therapeutics ( $TCRX ), setting the rating to Buy with a target price of 10 → 7.

1 · Reply

Deliver1 Nov. 12 at 10:38 PM

$TCRX November 2025 Corporate Presentation - MUST READ! https://ir.tscan.com/static-files/1d066354-1ed3-4f4f-b97b-28806d9da9f5

0 · Reply

Elaine_Shrimp Nov. 12 at 8:24 PM

$TCRX found this through twitter 🤫🤫👀

0 · Reply

RMND Nov. 12 at 5:26 PM

$TCRX

0 · Reply

d_risk Nov. 12 at 4:26 PM

0 · Reply

Deliver1 Nov. 12 at 1:57 PM

$TCRX TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update https://finance.yahoo.com/news/tscan-therapeutics-reports-third-quarter-120000677.html

0 · Reply

PiratesKingLuffy Nov. 12 at 3:09 AM

0 · Reply

SPYmyQQQ Nov. 11 at 8:43 PM

🎯 Target Hit 🏁 📨 From Nov 10, 2025 💊 $TCRX 💵 Entry: $1.0600 ✅ Exit: $1.2300 💰 P/L: +16.04% 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

acarsoy Nov. 11 at 8:12 PM

$TCRX up 6% since morning entry. So far so good

0 · Reply

RMND Nov. 11 at 7:47 PM

$TCRX

0 · Reply

SQUEAKSBANDIT Nov. 11 at 3:28 PM

$TCRX flipped em @ 1.13 means you'll likely see 1.25 before the days out gl

0 · Reply

acarsoy Nov. 11 at 3:27 PM

$TCRX has potential

0 · Reply

Scientific_Swings Nov. 11 at 2:24 PM

$TCRX

0 · Reply

Bullshyte Nov. 11 at 6:42 AM

$TCRX

0 · Reply

SPYmyQQQ Nov. 10 at 7:02 PM

🚀 New Signal ✅ 💊 $TCRX 🗓️ Nov 10, 2025 💵 Entry: $1.06 🎯 Target (Opt.): $1.23 (+16.04%) 👉 FREE TRIAL! spymyqqq/join/

0 · Reply

SQUEAKSBANDIT Nov. 10 at 4:42 PM

$TCRX this has been an awful earnings season but this close to a buck i'm willing to take some

0 · Reply

RMND Nov. 10 at 4:36 PM

$TCRX looks like it's going to dump before earnings...

0 · Reply

Deliver1 Nov. 10 at 1:25 AM

$TCRX Interesting excerpt regarding TCRX, from Zack's article on Novavax: "revenues are expected to be $3.2 milion, up 205.1% from the year-ago quarter" "One other stock from the same industry, TScan Therapeutics, Inc. (TCRX), is yet to report results for the quarter ended September 2025. This company is expected to post quarterly loss of $0.35 per share in its upcoming report, which represents a year-over-year change of -40%. The consensus EPS estimate for the quarter has been revised 0.7% higher over the last 30 days to the current level. TScan Therapeutics, Inc.'s revenues are expected to be $3.2 million, up 205.1% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report" https://finance.yahoo.com/news/novavax-nvax-reports-q3-loss-141503172.html

0 · Reply

Deliver1 Nov. 8 at 2:54 AM

$TCRX TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027 https://finance.yahoo.com/news/tscan-therapeutics-reaches-agreement-fda-113000348.html Lots of good info in that update. Any ideas on why the stock was massacred this past week?

0 · Reply

Arcides Nov. 7 at 5:23 PM

$TCRX poor boy, destroyed this week.

2 · Reply

Market Cap	67.53M
Revenue (ttm)	2.82M
Net Income (ttm)	-127.50M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-4,521.28%
Debt to Equity Ratio	0.18

Volume	515,500
Avg Vol	709,304
Day's Range	N/A - N/A
Shares Out	56.75M
Stochastic %K	24%
Beta	1.00
Analysts	Strong Sell
Price Target	$6.50